(Q36742400)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17316150%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

review article

1 reference

title

Clinical pharmacokinetic monitoring of midazolam in critically ill patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17316150%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17316150%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

Sean P Spina

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17316150%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

language of work or name

English

0 references

publication date

1 March 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17316150%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17316150%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17316150%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17316150%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

389-398

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17316150%20AND%20SRC:MED&resulttype=core&format=json

Midazolam disposition in patients undergoing continuous venovenous hemodialysis

26 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

The use of sedative agents in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Pharmacokinetics and pharmacodynamics of midazolam given via continuous intravenous infusion in intensive care units

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Sedation in PACU: the role of benzodiazepines

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Midazolam therapeutic drug monitoring in intensive care sedation: a 5-year survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Prolonged sedation due to accumulation of conjugated metabolites of midazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Clinical pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Possibility of Influence of Midazolam Sedation on the Diagnosis of Brain Death: Concentrations of Active Metabolites after Cessation of Midazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Failure of critically ill patients to metabolise midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Pharmacokinetics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Monitoring sedation, agitation, analgesia, neuromuscular blockade, and delirium in adult ICU patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Controlled Sedation with Alphaxalone-Alphadolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

A rapid high-performance liquid chromatographic method for the measurement of midazolam plasma concentrations during long-term infusion in ICU patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Determination of midazolam and its major metabolite 1'-hydroxymidazolam by high-performance liquid chromatography-electrospray mass spectrometry in plasma from children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Analysis of omeprazole, midazolam and hydroxy-metabolites in plasma using liquid chromatography coupled to tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

A sensitive, rapid and specific determination of midazolam in human plasma and saliva by liquid chromatography/electrospray mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Comparison of high-performance liquid chromatography and polyclonal fluorescence polarization immunoassay for the monitoring of midazolam in the plasma of intensive care unit patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

The effect of age on the pharmacokinetics and pharmacodynamics of midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Sedation assessment in critically ill adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Differentiating midazolam over-sedation from neurological damage in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Is the bispectral index appropriate for monitoring the sedation level of mechanically ventilated surgical ICU patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Bispectral index monitoring in the intensive care unit provides more signal than noise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389

Complications of sedation with midazolam in the intensive care unit and a comparison with other sedative regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.389